Ceva Launches TULAVEN - A New Addition To Its Range Of Treatments For BRD
3 years ago 
1071 views
Ceva Animal Health has extended its comprehensive range of treatments for Bovine Respiratory Disease (BRD) with the launch of TULAVEN 100mg/ml.
Containing the well-known and trusted active ingredient, tulathromycin, TULAVEN is licensed for the treatment and metaphylaxis* of BRD associated with Mannheimia haemolytica, Pasteurella multocida, Histophilus somni and Mycoplasma bovis. It joins Ceva’s popular and extensive range of BRD treatments, which includes ZELERIS, FLORKEM, MELOXIDYL and ALLEVINIX. This, in addition to Ceva-owned Ridgeway Biologicals which has the facility to develop autogenous vaccines, enhances Ceva’s expertise in the treatment of BRD.
TULAVEN can also be used to treat Infectious Bovine Keratoconjunctivitis (IBK) associated with Moraxella bovis as well as Porcine Respiratory Disease Complex (PRDC) associated with Actinobacillus pleuropneumoniae, Pasteurella multocida, Mycoplasma hyopneumoniae, Haemophilus parasuis and Bordetella bronchiseptica.
To enhance Ceva’s range of sheep products, TULAVEN is licensed to treat the early stages of infectious pododermatitis (foot rot) in sheep associated with virulent Dichelobacter nodosus.
TULAVEN is the first and only tulathromycin available in innovative CLAS (Ceva Layered Anti Shatter) vials. These shock resistant1 plastic vials have 33 per cent less impact on the environment from cradle to grave than glass vials2. With 99% of farmers preferring to use CLAS vials over glass3, the easy to use, practical and eco-friendly CLAS vials are not only robust and shock resistant for less breakage, spillage and losses, but the ergonomic ‘grip groove’ ensures easier handling4, while the light weight material makes the vials easier to transport5.
Cuneyt Seckin, managing director of Ceva Animal Health UK and Ireland, says: “Ceva has been developing its expertise in the treatment of BRD for many years, with a wide range of treatment options and autogenous vaccines available for vets. The launch of TULAVEN is the next addition to this range, enabling us to offer even more support to vets and farmers.”
Peter Keyte, ruminant business unit manager at Ceva Animal Health, adds: “We are delighted to add the trusted and affordable tulathromycin, TULAVEN, to our range. It complements our extensive BRD portfolio of products, including ZELERIS, FLORKEM, MELOXIDYL and ALLEVINIX, most of which will be available in CLAS shatterproof vials from 2021, making them ideal for farm conditions.”
For further information on TULAVEN please contact your local Ceva territory manager, call Ceva on 01494 781510 or email [email protected].
* As per the SPC, presence of the disease in the herd should be established before starting metaphylactic treatment.
Ends
References
- Cavaroc P. J. et al. – Comparative breakage study of injectable anti-infectives vials under vertical drop test by free fall under standardized conditions. IPVS Congress, 2012, 100
- Jacquet C. et al. Comparative life cycle analysis, final report with critical review, CLAS packaging system and traditional glass packaging system. 2016, APESA 0393 Impact 2002 fig 18 p33, fig.21 p36
- Lacoste (2011) Study Report Ceva Sante Animal Health. GAL-SLA-C581.0-11030-N. Usage survey conducted on 540 farmers in France
- CLAS vials reference book (2012). Section 5.2: Artis Factis and Ceva developed hand zone ergonomic study (2003). P 16
- CLAS vials reference book (2012). Section 5.4: Comparison of the weight of CLAS vials vs. glass vials showing that CLAS vials are 6 X lighter than glass vials of the same size. P19
More from Ceva
13 hours ago